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Background
Cancer-testis antigens (CTAs) are a group of proteins
whose expression is essentially restricted to testis germ-
line cells among normal somatic cells. CTAs also pos-
sess a heightened expression in many different types of
cancer. Due to their restricted expression in tumor cells
among MHC class I-expressing cells, there has been
interest in the CTA as essentially tumor-specific targets
for CD8+ T cell-directed therapies. Amongst the CTA
genes is the Synovial Sarcoma X chromosome break-
point (SSX) gene family. There are ten members of the
SSX family with a high degree of homology amongst
them. SSX-2 is the most commonly expressed member
of the SSX family, and serves as a prototypical member
for study. We have previously demonstrated that SSX-2
expression is confined to metastatic tissue, and is not
detected in primary prostate tumors. The function of
the SSX family is largely unknown, and further insights
into its function may reveal avenues for future directed
therapies.
Methods
We determined the pattern of SSX-2 expression in
patient peripheral blood; RT-PCR was used on periph-
eral blood samples from patients with prostate cancer as
well as healthy controls. To determine the identity and
prevalence of SSX family members in metastatic tissue,
cDNA from metastatic tissue was examined by PCR
with primers specific for each SSX family member. To
further understand SSX-2’s function, SSX-2 expression
was knocked down in the 22Rv1 cell line using an
siRNA plasmid. This cell line was then assayed for
tumorigenicity (soft agar colony formation), prolifera-
tion, and invasion (wound healing assay). Finally using
qPCR, expression levels of markers of the epithelial to
mesenchymal transition (EMT) were examined in the
knocked down 22Rv1 cell line.
Results
We have detected SSX-2 mRNA in the peripheral
blood of 17 of 33 (51%) patients with prostate cancer
with circulating prostate tumor cells and 0% (0 of 5)
control blood donors without prostate cancer. SSX-2
was found to be in 47% (7/15) of metastatic cDNA
samples, SSX-1 was found at a lower rate (1/15), and
no additional family members were detected. In an
SSX-2 knockdown of the 22Rv1 cell line, EMT markers
Slug and Vimentin were shown to have their expres-
sion modulated. Additionally, the 22Rv1 SSX-2 knock-
down line has demonstrated a higher capacity to form
colonies in soft agar.
Conclusions
Due to SSX-2’s is preferential expression, as well as the
effect of SSX knockdown on known EMT markers and
soft agar colony formation, we believe that SSX-2 is
involved in the EMT process, and potentially in the pro-
gression of prostate cancer to metastatic disease.
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